TS-057778 — A novel monoclonal antibody (PIIO-1) to be used in combination with immune-checkpoint blockers. PIIO-1 augments CD8+ T cells-induced anti-tumor immunity and overcomes ICB resistance by disrupting transforming growth factor-β (TGF-β), the center of a pathway significantly implicated in solid tumors and hematological malignancies. PIIO-1 inhibits TGFβ locally via a docking receptor, avoiding adverse and unforeseen side effects.

TS-057777 — A novel orally-active drug molecule that can inhibit pathological CD4+ T-cells at clinically translatable doses and, blunts progressive cardiac dysfunction and left-ventricular (LV) remodeling during Heart Failure (HF).

TS-057776 — A novel protein-drug conjugate of human serum albumin chemically conjugated to SN-38, solubilizing the potent chemotherapeutic. This therapy has the potential to treat many tumors with poor prognosis, including pancreatic, lung, breast, colorectal, ovarian, sarcoma, head and neck cancer, urothelial malignancies, and others.

TS-057739 — CRISPR/Cas 9 mediated targeting of MIR155HG in primary human T cells creates genomic deletions that disrupt transcription of mature microRNA-155 (miR-155, a miR associated with inflammation). Applying this treatment to donor T cells prior to allogenic hematopoietic stem cell transplantation (allo-HSCT) when treating hematological malignancies and other primary bone marrow disorders can prevent the development of aGVHD in patients.

TS-054471 — Knee templating is used as part of the pre-operative planning for knee replacement to determine the best fit for an implant. The current assistive devices used to determine fit are unreliable and inaccurate for proper patient fit. A new device is suggested to overcome these limitations.

TS-053103 — Uncontrolled hemolysis (i.e., destruction of red blood cells) is characterized by the increase of circulating toxic cell-free hemoglobin, heme and iron in the bloodstream. In vivo, the body’s natural supply of plasma scavenger proteins acts to neutralize these toxic species. However, these scavenger proteins such as haptoglobin, hemopexin and transferrin, which detoxify hemoglobin, heme and iron, respectively, are depleted in various clinical conditions such as hemorrhagic shock, burns, surgery, organ transplantation, sepsis and trauma. Dr. Andre Palmer’s lab at The Ohio State University has developed a novel therapeutic protein mixture, which can be used to treat plasma protein imbalances or depletion caused by the adverse events described above. The properties of this protein mixture are beneficial as they lend themselves to an inexpensive manufacturing process and potential improvements in clinical outcomes.

TS-051663 — Alleviate and prevent occupational stresses using this novel scalpel design.

TS-051298 — MicroRNAs (miRNAs) are small non-coding RNAs that control gene expression post-transcriptionally. Their sequences differ, but their lengths fall within a range of ~20-23 nucleotides because the precursor miRNAs are processed by Dicer. Dicer cleaves long double-stranded RNA (dsRNA) molecules into s…

TS-050524 — Despite high vaccine coverage, whooping cough caused by Bordetella pertussis remains one of the most common vaccine-preventable diseases worldwide. Introduction of whole-cell pertussis (wP) vaccines in the 1940s and acellular pertussis (aP) vaccines in 1990s reduced mortality due to pertussis. Des…

TS-050433 — A gene therapy solution for Usher Syndrome Type 1F.

TS-050296 — A sequencing-based diagnostic assay for SARS-CoV-2 with sensors of immune activation and the viral microbiota.

TS-050245 — An integrated platform with multiple sensing modalities to actively orchestrate antimicrobial activity and wound healing.

TS-050238 — Methods of purifying proteins that can be used in various applications such as drug delivery, bioimaging and hemolysis treatment.

TS-050220 — Novel natural products and derivatives thereof that exhibit potent in vitro and in vivo activity

TS-050057 — A method for manufacturing surgical tools and implants with strong, gapless joints between NiTi (Nitinol) and stainless steel to capitalize on the best properties of both materials.

TS-049827 — circPCMTD1 is a novel target in p53 mutated leukemias.

TS-049730 — Dysregulated fat metabolism is an established hallmark of cancer cells. However, the disruption of lipid homeostasis in cancer cells remains an elusive target for therapy. Tumor cells acquire abundant fats for rapid cell growth, but how they avoid toxicity from such loading is unknown. An answer t…

TS-049505 — An engineered base editor (iABE-NG) that uses an SpCas9 variant, a shortened adenine deaminase domain with eliminated RNA off-target activity, and an intein split for packaging into an adeno-associated virus (AAV), resulting in gene mutation correction.

TS-049471 — Listeriosis is an infectious disease caused by the bacterial pathogen Listeria monocytogenes. Although the average number of cases is moderate in the United States (1600-2500/year), listeriosis is a significant health concern due to its exceptionally high fatality rate. Indeed, listeriosis is the …

TS-047118 — Analogues of verticillin with significantly improved drug-like properties, including increased solubility, absorption, and stability, while maintaining similar anticancer potency as the verticillin parent compounds.